Tuesday broker round-up
13th Jul 2021 12:58
(Sharecast News) - Dr Martens: Goldman Sachs upgrades to buy with a target price of 535p.
Read moreStronger-than-expected trading continues through year-end at Dechra
12th Jul 2021 07:43
(Sharecast News) - Dechra Pharmaceuticals reported on Monday that the stronger-than-expected trading it outlined in early June had continued for the rest of its financial year, as expected.
Read moreTuesday broker round-up
8th Jun 2021 13:54
(Sharecast News) - tinyBuild: Berenberg reiterates buy with a target price of 295p.
Read moreDechra Pharmaceuticals FY revenue to beat market expectations
8th Jun 2021 07:30
(Sharecast News) - Dechra Pharmaceuticals said on Tuesday that full-year revenue was set to be ahead of consensus expectations, as it continues to benefit from strong market fundamentals and lower costs.
Read moreDirector dealings: Dechra director lowers stake
16th Apr 2021 16:10
(Sharecast News) - Dechra Pharmaceuticals revealed on Friday that director Tony Griffin had sold 25,000 ordinary shares in the FTSE 250-listed veterinary drugmaker.
Read moreThursday broker round-up
11th Mar 2021 13:28
(Sharecast News) - Hunting: RBC Capital Markets downgrades to sector perform with a target price of 305p.
Read moreFriday broker round-up
26th Feb 2021 13:47
(Sharecast News) - Reckitt Benckiser: Credit Suisse reiterates outperform with a target price of 7,800p.
Read moreDechra Pharmaceuticals' interim revenues and profits improve
22nd Feb 2021 08:43
(Sharecast News) - Drugmaker Dechra Pharmaceuticals said on Monday that reported group revenues and operating profits had both increased throughout the six months ended 31 December.
Read moreDechra secures last international rights to Tri-Solfen
8th Feb 2021 07:54
(Sharecast News) - Dechra Pharmaceuticals announced on Monday that it has secured the rights to market Tri-Solfen in Australia and New Zealand. and has acquired a further 1.5% of Medical Ethics for AUD 32.5m (£18.1m).
Read moreThursday broker round-up
26th Nov 2020 13:57
(Sharecast News) - AO World: Jefferies downgrades to hold with a target price of 378p.
Read moreJP Morgan raises target price on Dechra Pharmaceuticals
26th Nov 2020 10:31
(Sharecast News) - Analysts at JP Morgan Cazenove raised their target price on veterinary pharmaceuticals group Dechra from 3,200.0p to 3,600.0p on Thursday, stating they expect a year of "strong topline growth" to take place in 2021.
Read moreDirector dealings: Dechra executive makes share sale
2nd Oct 2020 15:08
(Sharecast News) - Dechra Pharmaceuticals revealed on Friday that executive director Paul Sandland had sold 2,474 ordinary shares in the FTSE 250-listed veterinary drugmaker.
Read moreFriday broker round-up
11th Sep 2020 13:47
(Sharecast News) - Vistry: JP Morgan upgrades to neutral with a target price of 670.0p.
Read moreDechra Pharma lifts dividend as FY profits rise
7th Sep 2020 07:03
(Sharecast News) - Veterinary drugs firm Dechra Pharmaceuticals reported higher full year profits and raised its dividend as it made an "encouraging" start to the new fiscal year.
Read moreMonday broker round-up
24th Aug 2020 10:57
(Sharecast News) - Dechra Pharmaceuticals: Liberum initiates at sell with a target price of 2,740p.
Read more